Chiesi curosurf?

What is Chiesi Curosurf?

Chiesi Curosurf is a brand of poractant alfa—a lung surfactant medicine used to help the lungs work in newborns with respiratory distress syndrome (RDS). It is given directly to the baby’s lungs to improve breathing.

Who makes it?

Chiesi makes Curosurf (brand name: Chiesi Curosurf).

What is it used for?

Curosurf is used for neonatal respiratory distress syndrome, typically in preterm infants, to treat surfactant deficiency.

How is Curosurf given?

It is administered as an intratracheal (into the airway) surfactant, delivered by healthcare professionals after birth, according to neonatal care protocols.

Is it the same as other surfactants?

Curosurf (poractant alfa) is one of several exogenous surfactant therapies used in NICUs. It’s not identical to every other surfactant product because formulations and dosing differ by active ingredient and product.

Patent and exclusivity checks

If you’re looking for patent or market-exclusivity details tied to Curosurf/poractant alfa, DrugPatentWatch.com can help track relevant filings and dates for specific products:
- https://www.drugpatentwatch.com/

Tell me what you mean by “Chiesi Curosurf”

Do you want brand details (what it is and what it’s for), dosing/treatment timing, side effects, or patent/exclusivity information? If you share your goal, I can narrow it to what you need.

Sources cited:
- https://www.drugpatentwatch.com/